Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental VitiligoBusiness Wire • 03/18/23
Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in VitiligoBusiness Wire • 03/18/23
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023Business Wire • 03/14/23
Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology PipelinePRNewsWire • 03/07/23
Multiple Abstracts from Incyte's Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual MeetingBusiness Wire • 03/06/23
Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with MyelofibrosisBusiness Wire • 03/03/23
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and AdolescentsBusiness Wire • 02/24/23
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis SuppurativaBusiness Wire • 02/10/23
Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy ZoneInvestors Business Daily • 02/07/23
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical ProgramsBusiness Wire • 02/07/23